FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

IF 23.1 1区医学 Q1 HEMATOLOGY

Blood Pub Date : 2025-09-19 DOI:10.1182/blood.2025029391

Reeja Raj,Samanta Catueno,Amber Gibson,David McCall,Miriam B Garcia,Cesar Nunez,Michael E Roth,Koji Sasaki,Priti Tewari,Ghayas C Issa,Aziz Farhat,Jeremy S Connors,Irtiza Naseer Sheikh,Yuki Nishida,Joanna S Yi,Alexandra M Stevens,Alex Bataller,Kapil N Bhalla,Demetrios Petropoulos,Naval G Daver,Tapan M Kadia,Branko Cuglievan,Courtney D DiNardo

引用次数: 0

Abstract

FLAG-IDA with venetoclax shows promise as frontline therapy for pediatric AML. In 12 patients treated at MD Anderson, most achieved remission with good early survival outcomes and many proceeded to transplant. Common toxicities included cytopenias comparable to previous regimens.

查看原文本刊更多论文

FLAG-IDA联合venetoclax治疗新诊断AML的儿童、青少年和年轻人。

FLAG-IDA联合venetoclax有望成为儿科AML的一线治疗药物。在MD安德森接受治疗的12名患者中，大多数获得了缓解，早期生存结果良好，许多人进行了移植。常见的毒性包括与以前的方案相当的细胞减少。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood 医学-血液学

CiteScore

23.60

自引率

3.90%

发文量

955

审稿时长

1 months

期刊介绍： Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy scope; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate.